1. Home
  2. PLSM vs ITRM Comparison

PLSM vs ITRM Comparison

Compare PLSM & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLSM

Pulsenmore Ltd. Ordinary Shares

N/A

Current Price

$4.65

Market Cap

22.0M

Sector

Health Care

ML Signal

N/A

Logo Iterum Therapeutics plc

ITRM

Iterum Therapeutics plc

HOLD

Current Price

$0.03

Market Cap

24.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLSM
ITRM
Founded
2014
2015
Country
Israel
Ireland
Employees
63
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.0M
24.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
PLSM
ITRM
Price
$4.65
$0.03
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$9.00
AVG Volume (30 Days)
29.0K
30.9M
Earning Date
03-30-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.43
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$947.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.00
$0.03
52 Week High
$7.15
$1.16

Technical Indicators

Market Signals
Indicator
PLSM
ITRM
Relative Strength Index (RSI) 61.96 26.10
Support Level $3.70 N/A
Resistance Level $5.00 $0.39
Average True Range (ATR) 0.50 0.02
MACD 0.16 -0.01
Stochastic Oscillator 31.77 3.34

Price Performance

Historical Comparison
PLSM
ITRM

About PLSM Pulsenmore Ltd. Ordinary Shares

Pulsenmore Ltd is an emerging medical device company engaged in the research, development, manufacturing, marketing, and sale of non-invasive portable ultrasound solutions for home use. Its products include the Pulsenmore ES and Pulsenmore FC, along with the early-stage Pulsenmore MC, collectively referred to as Pulsenmore Products, enabling remote ultrasound scans in gynecology and other fields such as pulmonary, cardiology, and urology through telemedicine. The Company operates in a single segment focused on developing and commercializing portable ultrasound technologies, with Israel contributing the majority of its revenue.

About ITRM Iterum Therapeutics plc

Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.

Share on Social Networks: